Areas of Focus
- 肿瘤精准治疗
- 临床大数据挖掘研究
- 临床需求为导向的医学转化与药物研发
Work Experience
- 2017-至今: 副研究员,复旦大学药学院
- 之前: 新药研发与基础研究,上药集团和第二军医大学附属长海医院
Academic Background & Achievements
- 1995-1998: 药剂学学士和硕士学位,沈阳药科大学
- 2009: 医学博士,第二军医大学
- 2010-2012: 博士后研究,中科院药物所和阿尔伯塔大学
- 在Nature Biotech, Theranostics, Pharmacol Res, Adv Mater等刊物发表30余篇SCI论文
- 授权10项专利
- 主编4项专著
- 主持30多项新药研发项目
Publications
- The global patent landscape of mRNA for diagnosis and therapy, M Lv, J Chen, Y Peng, L Gong, F Han, J Guo, L Tian, Y Gao, 2023
- Nitric oxide-loaded bioinspired lipoprotein normalizes tumor vessels to improve intratumor delivery and chemotherapy of albumin-bound paclitaxel nanoparticles, Wu Y, Xie H, Li Y, Bao X, Lu G, Wen J, Gao Y, Li Y, Zhang Z, 2023
- Mechanisms of sunitinib resistance in renal cell carcinoma and associated opportunities for therapeutics, Y Wang, X Liu, L Gong, W Ding, W Hao, Y Peng, J Zhang, W Cai, Y Gao, 2023
- Biomimetic liposomal nanozymes improve breast cancer chemotherapy with enhanced penetration and alleviated hypoxia, Li J, Gong C, Chen X, Guo H, Tai Z, Ding N, Gao S, Gao Y, 2023
- Mechanisms of Enzalutamide Resistance and Therapeutic Strategies to Overcome it, Wang Y, Chen J, Gao Y, Xu C, 2021
- Regulatory oversight of cell-based therapy in China: government’s efforts in patient access and therapeutic innovation, Wu W, Wang Y, Tang Z, Gao Y, Huo Y, 2020
- Pediatric drug development in China: Reforms and challenges, Wu W, Tang Z, Chen J, Gao Y, 2019
- Identification of the Risks in CAR T-Cell Therapy Clinical Trials in China: A Delphi Study, Wu W, Huo Y, Ding X, Gao Y, 2020
- SREBP1 siRNA enhance the docetaxel effect based on a bone-cancer dual-targeting biomimetic nano-system against bone metastatic castration-resistant prostate cancer, Chen J, Wu ZJ, Ding WH, Xiao CW, Gao S, Gao Y, Cai W, 2020
- Co-delivery of autophagy inhibitor ATG7 siRNA and docetaxel for breast cancer treatment, Gong C, Hu C, Gu F, Xia Q, Yao C, Zhang L, Qiang L, Gao S, Gao Y, 2017
Awards
- 2005: 上海市“新长征突击手”